JPRN-UMIN000015632已完成未知
eo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcer - NAC DS
Department of Frontier Surgery, Graduate school of Medicine, Chiba University0 个研究点目标入组 20 人开始时间: 2014年11月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Active double cancer. 2. Administration contraindication of TS-1 3. Continuous use of flucytosine, phenytoin or warfarin potassium 4. History of severe drug allergy (over grade 3) 5. Severe complications 6. infection or acute infectious disease 7. HBV or HCV positive 8. Severe watery diarrhea 9. Female who are pregnant, nursing, suspected of being pregnant or hope to become pregnant during the study period. 10. No birth-control 11. Psychosis or Psychiatric disorder 12. Sever edema to treat 13. History of severe peripheral nerve disorder (over grade 2) 14. HIV positive 15. Patients judged inappropriate for the study by their physicians
研究者
相似试验
已完成
2 期
Docetaxel and S-1 as adjuvant chemotherapy for pathological stage II, IIIA, IIIB gastric cancerPathological stage II, IIIa, or IIIb gastric cancerJPRN-UMIN000000857Dept. of Surgery and Science, Kyushu University20
已完成
不适用
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.Breast cancerJPRN-UMIN000002310Gunma Breast Cancer Research Group 2 surgery90
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
已完成
3 期
eoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: Evaluation of biological, clinical and imaging markers of tumour response.Cancer - BreastBreast CancerACTRN12605000588695Monash Health180
进行中（未招募）
不适用
eoadjuvant chemotherapywith weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advancedprostate cancer - docrtpchigh risk locally advancedprostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2008-003525-16-ITISTITUTI FISIOTERAPICI OSPITALIERI